Workflow
Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
Protara TherapeuticsProtara Therapeutics(US:TARA) GlobeNewswire News Room·2025-08-11 12:00

Core Insights - Protara Therapeutics, Inc. reported financial results for Q2 2025, highlighting ongoing clinical trials and business updates [1][10] Clinical Development - The company is advancing its pipeline, particularly the ADVANCED-2 trial of TARA-002 for non-muscle invasive bladder cancer (NMIBC), with interim results expected in Q1 2026 [2][7] - Protara is on track to initiate dosing in the THRIVE-3 trial of IV Choline Chloride for patients dependent on parenteral support by the end of Q3 2025, with EU enrollment anticipated soon [4][7] - The STARBORN-1 trial of TARA-002 in pediatric patients with lymphatic malformations is ongoing, with an interim update expected in Q4 2025 [5][7] Financial Performance - As of June 30, 2025, Protara had approximately $146 million in cash and equivalents, sufficient to support operations into mid-2027 [7][16] - Research and development expenses increased to $10.8 million in Q2 2025 from $6.4 million in the same period of 2024, primarily due to clinical trial activities [16][22] - The company reported a net loss of $15.0 million, or $0.35 per share, compared to a net loss of $9.5 million, or $0.45 per share, in Q2 2024 [16][23] Corporate Updates - William "Bill" Conkling was appointed as Chief Commercial Officer in June 2025, bringing over 20 years of experience in developing and commercializing novel therapeutics [6][9] - Protara was added to the Russell 3000® Index effective June 30, 2025, enhancing its visibility in the market [9]